SCHEMBL2446676

SCHEMBL2446676

Cc1cccc(O)c1C(F)(F)F

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 2/20 0.56
ATM Q13315 1/20 0.56
ALDH1A1 P00352 5/20 0.44
GABRA1 P14867 1/20 0.39
GABRB2 P47870 1/20 0.39
CA2 P00918 3/20 0.36
HPGD P15428 3/20 0.36
HSD17B10 Q99714 3/20 0.36
TDP1 Q9NUW8 3/20 0.36
EGFR P00533 2/20 0.36
CA1 P00915 2/20 0.36
LMNA P02545 2/20 0.36
FYN P06241 2/20 0.36
MMP9 P14780 2/20 0.36
ALOX15 P16050 2/20 0.36
RECQL P46063 2/20 0.36
ADAMTS4 O75173 1/20 0.36
MMP2 P08253 1/20 0.36
MMP8 P22894 1/20 0.36
CA6 P23280 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30503586 1.00 TRPA1 (0.56) TRPA1ATMALDH1A1GABRA1GABRB2
SCHEMBL5512574 0.83 TDP1 (0.45) TRPA1ATMALDH1A1CA2HPGD
SCHEMBL4090283 0.83 CYP2A6 (0.43) TRPA1ATMALDH1A1GABRA1GABRB2
SCHEMBL28179752 0.81 TRPA1 (0.42) TRPA1ATMALDH1A1GABRA1GABRB2
SCHEMBL6473329 0.79 TRPA1 (0.58) TRPA1ATMALDH1A1GABRA1GABRB2
SCHEMBL112587 0.79 TRPA1 (0.58) TRPA1ATMALDH1A1GABRA1GABRB2
SCHEMBL27700105 0.79 ATM (0.58) TRPA1ATMALDH1A1GABRA1GABRB2
SCHEMBL29664137 0.79 TRPA1 (0.58) TRPA1ATMALDH1A1GABRA1GABRB2
SCHEMBL6197878 0.79 ESR1 (0.37) TRPA1ATMALDH1A1HPGDHSD17B10
SCHEMBL11001536 0.78 CYP1A2 (0.48) TRPA1ATMALDH1A1GABRA1GABRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4217062-B1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-10-09 EP disclosed
US-20240208902-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-06-27 US disclosed
WO-2024112853-A1 COMPOUNDS THAT INHIBIT PKMYT1 EXELIXIS, INC. (US) 2024-05-30 WO disclosed
CN-111989321-B KRAS G12C inhibitors 米拉蒂治疗股份有限公司 2024-05-14 CN disclosed
US-20240101553-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2024-03-28 US disclosed
US-20230373999-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-11-23 US disclosed
US-20230373999-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-11-23 US disclosed
US-20230373999-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-11-23 US disclosed
US-11802111-B2 Cyclobutyl amide monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-10-31 US disclosed
EP-4217062-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN Pharmaceutica NV (BE) 2023-08-02 EP disclosed
WO-2002021216-A2 POLYMERS AND PHOTORESIST COMPOSITIONS COMPRISING ELECTRONEGATIVE GROUPS SHIPLEY COMPANY, L.L.C. (US) 2002-03-14 WO disclosed
WO-2002021212-A2 FLUORINATED PHENOLIC POLYMERS AND PHOTORESIST COMPOSITIONS COMPRISING SAME SHIPLEY COMPANY, L.L.C. (US) 2002-03-14 WO disclosed
EP-1183020-A2 USE OF(-)(3-TRIHALOMETHYLPHENOXY) (4-HALOPHENYL)ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES, HYPERLIPIDAEMIA AND HYPERURICAEMIA METABOLEX, INC. (US) 2002-03-06 EP disclosed
US-6262118-B1 THERAPY OF TYPE 2 DIABETES IN A MAMMAL BY ADMINISTERING (-) 4-CHLOROPHENYL-(3-TRIFLUOROMETHYLPHENOXY)ACETIC ACID DERIVATIVE METABOLEX, INC. 2001-07-17 US disclosed
WO-2000074666-A2 USE OF (-) (3-TRIHALOMETHYLPHENOXY) (4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES, HYPERLIPIDAEMIA AND HYPERURICAEMIA METABOLEX, INC. (US) 2000-12-14 WO disclosed
CN-1076439-A The new derivative of 3-hydroxyanthranilic acid, Preparation Method And The Use ASTRA AB (SE) 1993-09-22 CN disclosed
EP-0298803-B1 PROCESS FOR THE PERHALOALKYLATION OF AROMATIC DERIVATIVES RHONE-POULENC CHIMIE (FR) 1991-09-04 EP disclosed
EP-0298803-A1 Process for the perhaloalkylation of aromatic derivatives RHONE-POULENC CHIMIE (FR) 1989-01-11 EP disclosed
US-4731450-A Process for perfluoroalkylation of aromatic derivatives RHONE-POULENC SPECIALITES CHIMIQUES (FR) 1988-03-15 US disclosed
EP-0206951-A2 Process for the perfluoroalkylation of aromatic derivatives RHONE-POULENC CHIMIE (FR) 1986-12-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240208902-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS MGLL, LPL, PNLIP TRPA1 1419/4885ATM 3465/4885ALDH1A1 472/4885
US-20240101553-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS TRPA1 4503/4885ATM 3528/4885ALDH1A1 3370/4885
US-11802111-B2 Cyclobutyl amide monoacylglycerol lipase modulators MGLL, LPL, PNLIP TRPA1 1434/4885ATM 3517/4885ALDH1A1 450/4885
US-20230373999-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS TRPA1 4503/4885ATM 3528/4885ALDH1A1 3370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.